Guides

Artificial intelligence is reshaping clinical trial operations in 2026. Sponsors and CROs are no longer evaluating standalone tools. They are choosing platforms that can connect with existing systems, automate complex workflows, and scale without disrupting ongoing studies. This guide breaks down the vendors best positioned to integrate with the clinical trial infrastructure you already have.

‍

Artificial Intelligence is rapidly transforming clinical research. From patient recruitment and protocol design to medical writing and data review, AI-powered solutions are becoming embedded across the clinical development lifecycle. More recently, the emergence of Agentic AI (systems capable of planning, reasoning, and executing multi-step workflows with varying degrees of autonomy) has generated significant excitement throughout the industry.

However, not all AI solutions are created equal. While many vendors promise dramatic improvements in efficiency and productivity, clinical trial organizations operate in one of the most highly regulated environments in the world. Success depends not only on technical performance but also on compliance, validation, governance, security, and trust.

As sponsors, CROs, and technology teams evaluate potential AI partners, they need a framework that extends beyond traditional software procurement criteria. The following considerations can help organizations assess both AI and Agentic AI vendors and identify solutions that are truly ready for clinical research.

‍

Medable is a Palo Alto-based platform that has positioned itself as a leader specifically in decentralized clinical trials (DCT), eCOA, and — most recently — agentic AI. It has been deployed in nearly 400 trials across 70 countries and 120 languages, serving more than one million patients globally, and has been recognized as a Leader in eCOA by Everest Group.

‍

AI-powered remote patient monitoring (RPM) is transforming clinical trials by enabling continuous data collection, real-time insights, and decentralized participation. This ecosystem spans wearables, AI analytics, data platforms, and decentralized clinical trial (DCT) infrastructure.

Additionally, agentic AI is fundamentally reshaping remote patient monitoring (RPM) in clinical trials by shifting it from passive data collection to proactive, autonomous decision support. Instead of simply aggregating data from wearables and patient-reported outcomes, agentic systems can continuously analyze multi-source trial data, identify emerging risks, and take action, such as prioritizing at-risk patients or sites, triggering alerts, or recommending interventions, without waiting for human input. This significantly reduces delays in detecting safety signals or protocol deviations. Just as importantly, agentic AI introduces workflow automation at scale by handling routine monitoring tasks, coordinating communications, and maintaining audit-ready reasoning trails. The result is a more adaptive and responsive RPM model where clinical teams move from manual oversight to strategic supervision, enabling faster, safer, and more efficient trials.

Below is a structured overview of the leading vendors, tools, and providers enabling AI-driven RPM in clinical research.

‍

Combining artificial intelligence (AI) and agentic AI with electronic Clinical Outcome Assessment (eCOA) systems fundamentally enhances how clinical trial data is collected, interpreted, and acted upon. At its core, eCOA captures structured data directly from patients, clinicians, or observers, such as symptom severity, quality of life, or functional outcomes. Modern platforms expand this further by supporting a full range of assessment types, including electronic patient-reported outcomes (ePRO), clinician-reported outcomes (eClinRO), observer-reported outcomes (eObsRO), and performance outcomes (ePerfO).

‍

Digital data capture has become essential to modern clinical research. Sponsors and research organizations increasingly rely on electronic outcome assessment tools to collect high quality patient data, reduce manual errors, and improve regulatory compliance.

Two terms appear frequently in this space: eCOA (electronic Clinical Outcome Assessment) and ePRO (electronic Patient Reported Outcome).

These terms are closely related. However, they are not interchangeable.

‍

Sometimes when teams deploy eCOA (electronic Clinical Outcome Assessment) in clinical trials, challenges can arise with operational planning, protocol design decisions, or workflow alignment. Below are some of the most common missteps observed across sponsors, CROs, and investigative sites.

1. Treating eCOA as a late-stage add-on

Many teams wait until protocol finalization or even after startup to plan eCOA implementation.

Why this causes problems

• Instrument licensing or translations may not be ready
• Build timelines get compressed
• Protocol schedules may not align with electronic workflows

Best practice
Plan eCOA during protocol design, especially when selecting instruments and defining visit schedules. 

‍

Electronic clinical outcome assessment (eCOA) systems have reshaped how patient-reported outcome measures are collected and managed in clinical trials. Clinical operations leaders are under more pressure than ever to ensure that the migration from legacy paper instruments to digital platforms not only improves trial efficiency but also preserves data integrity, supports regulatory acceptance, and enhances participant experience.

The transition from paper to electronic capture represents a paradigm shift toward more efficient, accessible, and reliable data collection. Done well, eCOA strengthens evidence generation while reducing burden for participants and sites alike. Done poorly, it risks measurement bias, loss of comparability, and regulatory challenges.

In this article, clinical operations leaders will find evidence-based best practices for migrating and implementing patient-reported measures as part of eCOA strategies. These recommendations are rooted in published industry guidance and emerging scientific consensus, and they reflect the evolving landscape of digital assessment technologies.

‍

The global eCOA (electronic clinical outcome assessment) solutions market was valued at over two billion dollars in 2025, and is projected to expand rapidly over the coming decade, driven by increased clinical trial activity, digital transformation efforts, and the integration of mobile, cloud, and AI-enabled tools for outcome measurement.

This growth reflects not just broader industry digitization, but an evolving expectation: that outcome data should be accurate, audit-ready through validated systems and controlled operational processes, and capable of supporting decentralized workflows.As more sponsors and CROs incorporate eCOA into their trial strategies and regulators continue to emphasize electronic data integrity the stakes of successful implementation have never been higher. 

Yet with greater adoption comes greater complexity: pitfalls around site burden, mid-study amendments, device logistics, and training gaps can undermine even the most advanced platforms if not thoughtfully addressed.

The good news? These common challenges can be anticipated and managed with practical, operationally aligned planning turning eCOA from a source of friction into a strategic advantage for trial success.

‍

Explore how artificial intelligence (AI) is fundamentally transforming every facet of clinical trials, from initial protocol design and patient recruitment to data management and regulatory approval. This comprehensive guide provides an authoritative, in-depth look at AI's role in accelerating drug development and improving patient outcomes, with special focus on emerging agentic AI technologies.

‍

Discover how Agentic AI is revolutionizing clinical trials by optimizing efficiency, accelerating drug development, and improving patient access to therapies.

‍